A Phase 1, Open-label, Randomized, Crossover Study in Two Panels of Healthy Adult Subjects to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-63623872/Oseltamivir Fixed-dose Combination Tablet and Single Agent Concept Formulations of JNJ-63623872 Compared to Their Respective Reference Formulation
Phase of Trial: Phase I
Latest Information Update: 31 May 2017
At a glance
- Drugs Oseltamivir/pimodivir (Primary) ; Pimodivir (Primary)
- Indications Influenza A virus infections
- Focus Pharmacokinetics
- Sponsors Janssen-Cilag
- 01 May 2017 Status changed from active, no longer recruiting to completed.
- 05 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 15 Mar 2017 Status changed from not yet recruiting to recruiting.